Abstract
The main goal of pharmacovigilance has always been considered the earliest possible identification and characterization of adverse drug reactions (ADRs), with the aim of issuing strategies to minimize as much as possible the exposure of patients to a risk that is not balanced by a major benefit. This process forces each new drug to pass through three different safety filters: preclinical studies, pre-authorization clinical trials and post-authorization studies, the latter including spontaneous reporting of ADRs and observational studies. Each of these filters has breaches that may delay the identification of risks related to the pharmacological treatment, with a consequent injury that accumulates overtime to such an extent to involve millions of people.
The choice for mankind lies between freedom and happiness, and for the great bulk of mankind happiness is better. George Orwell, 1984
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
de Almeida Vieira Lima LM, Nunes NG, da Silva Dias PG et al (2012) Implemented data mining and signal management systems on spontaneous reporting systems’ databases and their availability to the scientific community – a systematic review. Curr Drug Saf 7(2):170–175
Hauben M, Zhou X (2003) Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 26(3):159–186
Suissa S, Garbe E (2007) Primer: administrative health databases in observational studies of drug effects – advantages and disadvantages. Nat Clin Pract Rheumatol 3(12):725–732
de Vries F, Zeegers M, Goossens ME (2013) Pioglitazone and bladder cancer: two studies, same database, two answers. Br J Clin Pharmacol 76(3):484–485
Black C, Jick H (2002) Etiology and frequency of rhabdomyolysis. Pharmacotherapy 22(12):1524–1526
Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA et al (2008) The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 17(10):943–952
Huang YL, Moon J, Segal JB (2014) A comparison of active adverse event surveillance systems worldwide. Drug Saf 37(8):581–596
Coloma PM, Schuemie MJ, Trifiro G et al (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20(1):1–11
Avillach P, Coloma PM, Gini R et al (2013) Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc 20(1):184–192
World Health Organization. The anatomical therapeutic chemical classification system. http://www.who.int/classifications/atcddd/en/. Accessed 31 Jan 2016
World Health Organization. International Classification of Diseases. http://www.who.int/classifications/icd/en/. Accessed 31 Jan 2016
World Health Organization. International Classification of Primary Care, Second edition (ICPC-2). http://www.who.int/classifications/icd/adaptations/icpc2/en/. Accessed 31 Jan 2016
Health and Social Care Information Centre. Read Codes. http://www.hscic.gov.uk/. Accessed 31 Jan 2016
National Institute of Health. Unified Medical Language System (ULMS). https://www.nlmnih.gov/research/umls/. Accessed 31 Jan 2016
Patadia VK, Coloma P, Schuemie MJ et al (2015) Using real-world healthcare data for pharmacovigilance signal detection – the experience of the EU-ADR project. Exp Rev Clin Pharmacol 8(1):95–102
Patadia VK, Schuemie MJ, Coloma P et al (2015) Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm 37(1):94–104
Makadia R, Ryan PB (2014) Transforming the premier perspective hospital database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS (Wash DC) 2(1):1110
Xu Y, Zhou X, Suehs BT et al (2015) A comparative assessment of observational medical outcomes partnership and mini-sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf 38(8):749–765
Hripcsak G, Duke JD, Shah NH et al (2015) Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 216:574–578
Groenwold RH, Klungel OH, Altman DG et al (2013) Adjustment for continuous confounders: an example of how to prevent residual confounding. CMAJ Can Med Assoc J 185(5):401–406
Udo R, Tcherny-Lessenot S, Brauer R et al (2016) The risk of acute liver injury associated with the use of antibiotics-evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project. Pharmacoepidemiol Drug Saf 25 Suppl 1:47–55
Dreyer N, Blackburn S, Mt-Isa S et al. PROTECT pregnancy study: an exploratory study of self-reported medication use in pregnant women. http://www.imi-protect.eu/documents/DreyeretelPROTECTPregnancyStudy-AnExploratoryStudyofSelf-ReportedMedicationUseinPregnantWompdf. Accessed 23 Feb 2016
Ghosh R, Lewis D (2015) Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media. Expert Opin Drug Saf 14(12):1845–53
McGovern MP, Boroujerdi MA, Taylor MW et al (2008) The effect of the UK incentive-based contract on the management of patients with coronary heart disease in primary care. Fam Pract 25(1):33–39
Inch J, Watson MC, Anakwe-Umeh S (2012) Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf 35(10):807–818
Mercer K, Giangregorio L, Schneider E et al (2016) Acceptance of commercially available wearable activity trackers among adults aged over 50 and with chronic illness: a mixed-methods evaluation. JMIR mHealth uHealth 4(1), e7
Acknowledgment
The authors wish to thank Richard D. Boyce for his valuable comments and advice during the revision of this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Tuccori, M., Wallberg, M. (2017). Other Sources of Information for Monitoring Drug Safety: Now and in the Future. In: Edwards, I., Lindquist, M. (eds) Pharmacovigilance. Adis, Cham. https://doi.org/10.1007/978-3-319-40400-4_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-40400-4_17
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-40399-1
Online ISBN: 978-3-319-40400-4
eBook Packages: MedicineMedicine (R0)